Vasculitis is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Vasculitis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Vasculitis compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Vasculitis

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vasculitis overview

Vasculitis is a term that refers to a group of diseases that cause inflammation of the blood vessels, affecting both arteries and veins. Vasculitis can have various causes, such as genetic factors, infections, immune system disorders, blood cancers, or reactions to certain drugs. Vasculitis can affect different parts of the body, such as the skin, muscles, joints, nerves, lungs, heart, digestive system, kidneys, and eyes. Depending on the type and severity of vasculitis, the symptoms and complications may vary. Some common signs of vasculitis are fever, weight loss, fatigue, headache, joint pain, skin rash, and bleeding under the skin. Vasculitis can be diagnosed by blood tests, imaging tests, or biopsy of the affected tissue. Treatment options depend on the type and cause of vasculitis, but usually involve medications to reduce inflammation and prevent flare-ups.

For a complete picture of PTSR and LoA scores for drugs in Vasculitis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.